Foundation Medicine, Agios developing diagnostics for cancer drugs

04/5/2013 | GenomeWeb Daily News (free registration)

Foundation Medicine and Agios Pharmaceuticals agreed to jointly develop companion diagnostics for the latter's experimental cancer drugs. The two companies will seek to identify genomic mutations to determine which patients will benefit from Agios' new cancer metabolism inhibitors that target tumors with mutated IDH1 or IDH2 metabolic enzymes.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC